Home Blog

Radient Completes Acquisition of Tunaaaaroom Xtracts and Makes Corporate Announcements

0

Edmonton, Alberta–(Newsfile Corp. – January 28, 2022) – Radient Technologies Inc. (TSXV: RTI) (“Radient” or the “Company”), a commercial manufacturer of diverse, novel, and high-quality cannabis extracts and packaged products, is pleased to announce that it has successfully completed the Company’s previously announced acquisition of all of the issued and outstanding securities of Tunaaaaroom Xtracts Inc. (the “Target”), an Alberta cannabis company (the “Acquisition”). The terms of the Acquisition were set out in a share exchange agreement effective November 29, 2021, among the Company, the Target, and the Target’s shareholders, Tunaaaa Room Inc. and Pioneer Laboratory Nutraceuticals Ltd. (the “Share Exchange Agreement”). The Share Exchange Agreement was subsequently amended by an amending agreement effective January 6, 2022, pursuant to which Tunaaaa Room Inc. was replaced as a shareholder and vendor of the Target by its two shareholders. For more information about the Acquisition, please see the Company’s press release dated November 29, 2021, which is available under the Company’s SEDAR profile at www.sedar.com.

In consideration for the Acquisition, Radient issued a total of 70 million of its common shares at a deemed price of $0.12 per share (the “Payment Shares”) and 15 million common shares purchase warrants (the “Warrants”), pro rata, to the former shareholders of the Target. Each Warrant is exercisable by the holder to acquire one common share of Radient for $0.15 for a period of two years following completion of the Acquisition. The Payment Shares, Warrants and common shares underlying the Warrants are subject to a four-month hold period, expiring on May 29, 2022. As additional consideration, Radient agreed to issue up to an additional 25 million of its common shares (the “Performance Shares”), pro rata, to the vendors of the Target at a deemed price of $0.12 per share upon the satisfaction of certain performance targets set out in the Share Exchange Agreement, as amended. The Performance Shares, if any, shall be subject to a hold period expiring four months following the date of issuance. Radient will also pay royalties of 1% of all revenue generated by the Company from sales of certain products pro rata to two of the vendors of the Target and the sole shareholder of Pioneer Laboratory Nutraceuticals Ltd., subject to certain conditions and limitations set out in the Share Exchange Agreement, as amended.

The Acquisition is an arm’s length transaction for the purposes of the policies of the TSX Venture Exchange (“TSXV”) and remains subject to final approval of the TSXV. Radient did not pay any finder’s fees in connection with the Acquisition.

Tunaaaaroom Extracts Inc. entered a licensing and co-develop agreement with Radient in December 2020 for development and sales of premium cannabis products, which are now sold through provincially licensed retailers in seven Canadian provinces and territories.

Corporate Announcements
Radient announces that it has completed its previously announced shares for debt settlements of $281,500 owed to various third-party creditors (the “Shares for Debt Settlement”) after being granted approval by the TSXV. Pursuant to the Shares for Debt Settlement, the Company has issued 4,691,668 common shares, all of which are subject to a four month and one day hold period expiring on May 29, 2022. For more information about the Shares for Debt Settlement, please see the Company’s press release dated December 31, 2021, which is available under the Company’s SEDAR profile at www.sedar.com.

Radient also announces that Mr. Yves Gougoux has resigned as director of the Company effective January 28, 2022, to pursue other interests. The board and management of the Company express their gratitude to Mr. Gougoux for his efforts and extensive contributions and wish him well in his future endeavours.

About Radient
Radient Technologies is a commercial manufacturer of diverse, novel and high-quality cannabis extracts and packaged products. Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Radient is focused on innovation with expertise in formulations and technologies offering unique solutions in the cannabis and wellness space. RadientInc.com

Contact Information:
Harry Kaura, CEO & Director
ir@radientinc.com
Ph: 780 465 1318

Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the Acquisition, including with respect to the issuance of the Performance Shares and royalty payments, as described in the Share Exchange Agreement, as amended. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; risks associated with operation in the cannabis sector; and other risks inherent in the cannabis industry. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112043

CENTR Brands Corp. Announces Q2 2022 Results

0

Vancouver, British Columbia–(Newsfile Corp. – January 28, 2022) – CENTR Brands Corp. (CSE: CNTR) (FSE: 303) (OTCQB: CNTRF) (the “Company“) today announced its financial results for the quarter ended August 31, 2021. Selected comparative financial information is set forth below with the full financial statements for the quarter and the related management’s discussion and analysis (“MD&A“) available under the Company’s SEDAR profile at www.sedar.com. All amounts are expressed in United States Dollars, unless otherwise stated:

Q2
2022
Q2
2021
Gross sales 373,319 417,064
Net sales 298,799 317,845
Net income (loss) and comprehensive income (loss) for the period (1) 834,512 (752,354)
Basic and diluted income
(loss) per share
0.01 (0.01)

 
(1) Q2 2022’s net income and comprehensive income for the period includes non-cash gains of $2,320,419 for the revaluation of warrants as a liability for accounting purposes.

Consumers can visit CENTR’s online store at: www.findyourcentr.com/shop.

About CENTR Brands Corp.

CENTR Brands Corp. is one of North America’s leading functional beverage companies. CENTR develops and markets non-alcoholic, functional ingestibles for the global market. The Company produces CENTR and CENTR Sugar Free, both sparkling, low calorie, CBD beverages as well as CENTR Instant, a family of on-the-go CBD powders. For more information visit www.findyourcentr.com, and follow on Instagram at @findyourcentr.

For further information, contact media@findyourcentr.com.

On behalf of the Board,

CENTR BRANDS CORP.

/s/ Joseph Meehan
Joseph Meehan, Chief Executive Officer

This press release may contain “Forward-Looking Statements” within the meaning of applicable Canadian securities laws. Actual results may differ from those indicated as a result of finalization of the Company’s financial statements as well as other risks and uncertainties. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112044

Global Hemp Group Provides Update of Its Green Community in Hayden, Colorado

0

Vancouver, British Columbia–(Newsfile Corp. – January 28, 2022) – GLOBAL HEMP GROUP INC. (CSE: GHG) (OTCQB: GBHPF) (FSE: GHG) (“GHG” or the “Company”) is pleased to provide an update on its development of the Green Community in Hayden, northwest Colorado.

Global Hemp Group and Western Sierra Resources Corporation (OTC: WSRC) have been working in close collaboration to develop this large scale enterprise – the sustainable Green Community in Hayden, Colorado. The collaboration began more than six years when in 2015 GHG’s Founder first walked the strategic project properties acquired by the Company in 2021. With the major confluence of multiple factors now occurring; sustainable construction in the forefront, a large pent up demand for affordable housing in the area, the national legalization of hemp in the United States, and the opportunities with hemp-based carbon credits, this is the perfect time to develop this project.

The collaboration utilizes GHG’s expertise in large scale hemp cultivation; processing; hemp-based research and development; manufacture of hemp-based construction products; in-house construction experience utilizing hemp-based materials; and financial resources to acquire suitable land for each of these hemp-based revenue centers.

The collaboration further utilizes WSRC’s 20 years of development expertise in the immediate market area to assemble land; provide the water resources necessary for large scale irrigation and cultivation of industrial hemp; obtain development approvals for manufacture of hemp-based products, and to build and market affordable homes to help meet pent up demand in local market.

To date GHG has invested US$1.9 million in this project.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2022/01/global-hemp-group-provides-update-of-its-green-community-in-hayden-colorado.jpg?w=696&ssl=1

Image 1

To view an enhanced version of Image 1, please visit:
https://grassnews.net/wp-content/uploads/2022/01/global-hemp-group-provides-update-of-its-green-community-in-hayden-colorado.jpg

Design of the 44 acre commercial/industrial property

The engineering and site design work for the 44-acre HAIZ project is nearing completion. Application for development approval was submitted to the Town of Hayden and the process is ongoing. After subsequent review and comment by the various County and State agencies, revisions will be made for final plan submission. GHG is working with its planners and engineers in collaboration with WSRC to coordinate efforts and coordinate the application elements as its local “boots on the ground” partner to shepherd this project through the approval process.

The first phase of the HAIZ project is a 7- acre portion of the 44 acre HAIZ campus. This commercial/industrial phase includes a 12,000 sq ft processing plant, 26,000 sq ft manufacturing facility, 10,000 sq ft showroom/administration building, 2 model homes and 12,000 sq ft greenhouse/R&D facility (see map above).

The processing plant will contain decortication and cottonization equipment to separate the harvested hemp into hurd, fibre, and powdered elements. These products will be inventoried for direct use at the on-site manufacturing facility, as well as for sale to third party manufacturers, and distributors of hemp-based products. The manufacturing facility will contain the equipment to produce hempcrete blocks and hempcrete panels that will be used in the construction of the Green Community.

Development of the Planned Unit Development (PUD)

Patten Associates, Inc. has been engaged to provide creative project management, land planning and design solutions for the project. An initial Concept Plan for the first phase of the development on the 166 acre residential parcel can be seen below.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2022/01/global-hemp-group-provides-update-of-its-green-community-in-hayden-colorado-1.jpg?w=696&ssl=1

Image 2

To view an enhanced version of Image 2, please visit:
https://orders.newsfilecorp.com/files/3292/112017_6a9f8c5224ec4bdc_003full.jpg

Residential housing and the reduction of its carbon footprint.

The Company continues to explore initiatives to reduce the carbon footprint of the homes that it will be constructing in Hayden, with the goal of building a truly Green and Sustainable Community. The Company will achieve this with the use of hempcrete (hemp block technology and pre-fab hemp panels) and other hemp-based building materials manufactured onsite in Hayden.

Typical residential housing has a heavy carbon footprint, made up of two components: operational and embedded. The operational footprint depends on the nature of energy used in the house. In today’s housing much has been done in reducing the operational footprint, but too often at the expense of a considerably heavier embodied carbon footprint. According to Proceedings of the National Academy of Sciences of the Untied States of America (PNAS) residential energy use accounts for roughly 20% of greenhouse gas (GHG) emissions in the United States.

Hempcrete construction (block and panel) responds to both operational and embedded carbon at the same time. It can reduce operational energy to the lowest possible amounts depending on the available energy source for heating and cooling, while reducing the embedded CO2 is less than 10% of conventional construction. Hemp construction locks away CO2 permanently, replacing carbon-laden housing.

Carbon market opportunities.

As the Hayden project is vertically integrated from farm to housing development it stands to sequester or lock in a sizeable amount of CO2e in soils as well as buildings and other products. Moreover, hempcrete buildings will replace current buildings that have a large, embodied carbon footprint. This provides an opportunity for the Company to enter the Voluntary Carbon Market, where GHG can supply ESG minded corporations with some of the credits they need to balance their carbon budget. The Company is also exploring the opportunities of being able to trade these credits with interested partners.

Management Cease Trade Order (MCTO)

The Company also announces that it anticipates a delay in the filing of the financial statements required pursuant to Part 4 of National Instrument 51-102 Continuous Disclosure Obligations (the “Instrument”) as a result of various individuals from the Management team of the Company and external audit team members contracting Covid-19 during various stages of the audit process. Consequently, the completion of the annual audit is taking longer than expected.

The Instrument requires that the Company’s audited financial statements and MD&A for the fiscal year ended September 30, 2021 be filed by January 28, 2022. The Company and its auditor are in the process of completing the associated audit work to complete these audited financial statements. The Company expects that the audited financial statements and MD&A for the year ended September 30, 2021 (collectively, the “Required Filings”) will be completed and filed on or before February 11, 2022.

In connection with the anticipated delays in making the Required Filings within the time periods mandated by the Instrument, the Company has applied for a management cease trade order (“MCTO”) under National Policy 12-203 Cease Trade Orders (“NP 12-203”) by the British Columbia Securities Commission, as principal regulator for the Company. The MCTO will restrict all trading by the Company’s CEO and CFO in securities of the Company, whether direct or indirect. The issuance of the MCTO will not affect the ability of persons who are not directors, officers or insiders of the Company to trade their securities. The MCTO will remain in effect until the Required Filings are filed or until it is revoked or varied.

The Company confirms that it intends to satisfy the provisions of the alternative information guidelines described in NP 12-203 by issuing bi-weekly default status reports in the form of a news release for so long as it remains in default of the requirement to make the Required Filings. The Company has no material information relating to its affairs that has not been generally disclosed.

Subscribe to the GHG YouTube Channel:

https://www.youtube.com/channel/UCtjFn9dOyHMxJee-_37MTrw

Like us on Facebook: https://www.facebook.com/globalhempgrp

Follow us on Instagram: https://www.instagram.com/hemp_global/

Follow us on Twitter: https://twitter.com/Hemp_Global

Connect with us on LinkedIn: https://www.linkedin.com/company/18596421

About Global Hemp Group Inc.

Global Hemp Group Inc. (CSE: GHG) (OTCQB: GBHPF) (FSE: GHG) is focused on a executing a multi-phased strategy to become a leader in the industrial hemp industry in the United States. The Company is headquartered in Vancouver, British Columbia. The current phase of the strategy focuses on the development of “sustainable” and “green” value-added industrial hemp products utilizing the processing of the entirety of the hemp plant for multi-merchantable applications, as will be showcased at the Colorado Hemp Agro-Industrial Zone (HAIZ) project in Hayden Colorado.

To further support and innovate the HAIZ, Global Hemp Group has established a Research and Development Division to actively pursue the development of Intellectual Property that can be patented for implementation at its projects and beyond. The Division is led by Prof. Víctor M. Castaño, Ph.D. from the National Autonomous University of Mexico (UNAM), a highly recognized leader in areas of applied science and technology. The R&D team brings an amazing wealth of knowledge and experience in multiple disciplines and will initially focus on development of Environmentally-Friendly Construction Materials, Nanofertilizers and Enhanced Extraction from Hemp.

For Further Information Contact Global Hemp Group
Curt Huber, President
Tel: 778-726-2900
info@globalhempgroup.com
www.globalhempgroup.com

Cautionary Note Regarding Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Global Hemp Group Inc., including, but not limited to the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk, the legality of cannabis and hemp. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Except as required by law, Global Hemp Group Inc. disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112017

Psyched Wellness Implements RSU Plan and Grant RSUS

0

Toronto, Ontario–(Newsfile Corp. – January 28, 2022) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, announced today that it has implemented a restricted share unit award plan (the “RSU Plan“). The following is a summary of the material provisions of the RSU Plan. It is not a comprehensive discussion of all of the terms and conditions of the RSU Plan and it is qualified in its entirety by the full text of the RSU Plan, a copy of which can be accessed on the Company’s SEDAR profile at www.sedar.com. Readers are advised to review the full text of the RSU Plan to fully understand all terms and conditions of the RSU Plan.

Adoption of RSU Plan

In order to further align the interests of the Company’s officers, directors, employees, and consultants with those of the shareholders of the Company, the board of directors the Company (the “Board“) have approved the implementation of the RSU Plan effective January 24, 2022 (the “Effective Date“). Under the RSU Plan, Eligible Persons (as such term is defined in the RSU Plan) may at the discretion of the Compensation Committee (as such term is defined in the RSU Plan), if so constituted, be allocated a number of restricted share units (“RSU“) as the Compensation Committee deems appropriate, with such vesting provisions to be determined by the Compensation Committee, subject to a maximum vesting term of three years from the end of the calendar year in which RSUs were granted. Upon vesting, Eligible Persons shall be entitled to receive common shares of the Company (the “Common Shares“) from treasury to satisfy all or any portion of a vested RSU award.

The maximum number of RSUs issuable under the RSU Plan is fixed at 13,058,969 (being 10% of the issued and outstanding Common Shares as of the Effective Date calculated on a non-diluted basis).

RSU Grants

In connection with implementing the RSU Plan, the Company announces that it has granted 9,300,000 RSUs to the certain Eligible Persons in accordance with the terms of the RSU Plan. Half of the RSUs granted vest immediately, with the other half vesting upon launch of the Company’s products. The Common Shares underlying the RSUs are subject to a four month hold period in accordance with the policies of the Canadian Securities Exchange (the “CSE“).

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com
Website: http://www.psyched-wellness.com

For media relations, please contact:

Anne Graf
KCSA Strategic Communications
agraf@kcsa.com
786-390-2644

Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; the uses and potential benefits of Amanita Muscaria; the Company becoming a leading North American brand in the emerging functional food category; and the future RSU grants made pursuant to the terms and conditions of the RSU Plan.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the Company’s ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; the continued growth of the Company; the Company becoming a leading North American brand in the emerging functional food category; and the Company granting future RSU awards to Eligible Persons pursuant to the terms and conditions of the RSU Plan.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; the risk that there is no potential benefit of Amanita Muscaria consumption; risks that the Company will not become a leading North American brand in the emerging functional food category; and risks of the dilution to Common Shares and any other adverse risks resulting from the adoption of the RSU Plan and issuance of awards thereunder.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111961

Red Light Holland’s Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program

0

Toronto, Ontario–(Newsfile Corp. – January 28, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to congratulate its partner CCrest Lab for being approved by Health Canada to supply Psilocybin to the new Special Access Program that would allow patients with conditions that are not treatable by other medication to get access to Psilocybin.

Red Light Holland has successfully imported their psilocybin truffles from the Netherlands to CCrest Laboratories twice where they were tested. Red Light Holland and CCrest Laboratories have continuously demonstrated their strong commitment to the highest regulatory compliance standards.

Red Light Holland hopes to continue to provide CCrest Laboratories with a source of their naturally occurring Psilocybin truffles, that would then be made available free of charge for patients who are eligible under the Special Access Program based on compassionate need.

“The new special access program is a great first step to increase access to psilocybin responsibly in Canada and our partners, CCrest Laboratories, have done amazing work to be approved by Health Canada as a supplier,” said Todd Shapiro, Chief Executive Officer and Director of the Company. “As a company we want to make a positive difference in this world, which is why we’d like to offer our lab tested Truffles via CCrest Labs, free of charge, to patients who are granted Special Access in Canada.”

“CCrest Labs and Red Light Holland are aiming to continue to work with the Canadian Government to ensure the success of this program, showcasing the groundbreaking naturally occurring psilocybin research we have been doing which has provided us extra knowledge on Red Light Holland’s products in the Netherlands. CCrest Labs and Red Light Holland have formed a great allegiance and we are completely aligned in the ‘compassionate need and free supply’ approach,” said Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories. “We’d like to thank Health Canada as well for their progressive views and continued support for allowing us to get two Psilocybin import licences to ship Red Light Holland products over international borders and for approving us to supply Psilocybin to the new Special Access Program.”

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.

For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

About Shaman Pharma Corp.

Shaman Pharma is an R&D incubator, strategic partner, and full-service laboratory to the global Psychedelics industry. Through its CDSA Narcotics Licence and regulatory/distribution expertise, the Company’s platform is helping emerging biotech entreprises to accelerate their innovations to market. A federally registered private corporation headquartered in Montreal, Canada, Shaman Pharma Corp. operates a growing portfolio of assets including Ccrest Laboratories and CBD Export Global. Visit www.shamanpharma.com for more information.

Forward-Looking Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to: statements with respect to the evaluation and testing of the Company’s naturally occurring psilocybe truffles by CCrest Laboratories for scientific and medical purposes; the potential of the Company’s products being used for scientific and medical purposes; the potential to supply the Company’s naturally occurring truffles for the Special Access Program; the potential for the Company to supply naturally occurring truffles via CCrest Labs for the Special Access Program through compassionate grounds; statements with respect to the Company’s expansion into the mental wellness pharmaceutical sector; the future sharing of the test results with the Company’s customers and shareholders; the Company and CCrest labs to get more of the Company’s product into Canada via a Health Canada approve Psilocybin import License, and the Company’s ability to establish itself as the leader in the recreational psychedelics sector.

Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: the COVID-19 pandemic impact on the Canadian economy and Red Light Holland’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Red Light Holland’s business; there will be a demand for Red Light Holland’s products in the future; no unanticipated expenses or costs arise; the Company will be able to continue to develop products that are allowed to be imported and sold under Health Canada’s import permit; and the partnership with Shaman Pharma Corp. will help Red Light Holland to achieve its business goals. Although the forward-looking information contained in this news release is based upon what the Company believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to continue as a going concern; the inability of the Company to obtain all necessary governmental and/or other regulatory approvals, licenses, and permits necessary to operate and expand the Company’s facilities; the effect of regulatory and/or political change and its effect on the legislation and regulations surrounding the psychedelics industry; negative perception of the medical-use and adult-use psilocybin industry; the inability of CCrest to complete the planned testing of the Company’s products; the potential unviability of psilocybin for medical and/or scientific purposes; the inability of the Company to continue its growth; the Company’s limited operating history; reliance on management; the Company’s requirements for additional financing; and competition for mental health and wellness investments.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111947

THE PARENT COMPANY ANNOUNCES VOLUNTARY EXTENSION OF BOARD OF DIRECTOR AND LEADERSHIP TEAM LOCK-UP AGREEMENTS

0

 

TPCO Holding Corp. (“The Parent Company” or the “Company”) (NEO: GRAM.U) (OTCQX: GRAMF), a leading vertically-integrated California cannabis company, announced today that certain insiders (the “Insiders”) have individually voluntarily entered into a twelve-month extension of lock-up agreements with the Company (the “Lock-Up Agreements”) with respect to an aggregate of over 34 million shares of common stock (“Lock-up Shares”), or approximately 35% of the total issued and outstanding shares of common stock of the Company as of January 28, 2022.

Pursuant to the Lock-Up Agreements, the Insiders have agreed to lock up the common shares that they directly own or over which they exercise control or direction through January 28, 2023. The Insiders are comprised of the entire Board of Directors, Michael AuerbachCarol BartzAl ForemanLeland HenschDaniel NeukommJeffry Allen, and Desiree Perez, and The Parent Company’s leadership team, including Troy Datcher, Chief Executive Officer, Mike Batesole, Chief Financial Officer, as well as additional senior team members.

“This voluntary extension demonstrates our Board of Directors’ and leadership team’s confidence in the long-term potential of our business,” said Troy Datcher, Chief Executive Officer of The Parent Company. “In the last year we have worked to expand our reach to over 80% of the adult population in California, triple our storefront presence, and deliver innovative new products for our customers. These initiatives support our goal to significantly expand our direct-to-consumer presence in California and provide customers with ease of access to high-quality products by meeting them where they are and how they like to shop.”

Mr. Datcher concluded, “With our well-known and robust branded products portfolio, expanded state-wide coverage and strong balance sheet, we believe this extended lock-up conveys the confidence we have in our ability to execute on the opportunities ahead in 2022 to generate long-term shareholder value.”

Under the terms of the Lock-Up Agreements, the Insiders have agreed, among other things, to not sell, pledge, assign, transfer, hypothecate or otherwise dispose of any of the Lock-up Shares, or enter into any swap, hedge or engage in any short-selling of the Lock-up Shares, without Company’ prior written consent. In addition to customary lock-up exceptions, the Lock-Up Agreements shall not apply to Insiders to the extent (i) any company with US cannabis operations (specifically operations that handle Tetrahydrocannabinol) is permitted to be listed on any senior US exchange, including the NYSE or Nasdaq, (ii) the trading price of The Parent Company’s common shares on the NEO Exchange Inc., or any other applicable stock exchange, exceeds US$10.00 at the close of any trading day or (iii) they cease to be a director, officer or employee of the Company.

Quinsam Declares 30th Consecutive Dividend

0

Toronto, Ontario–(Newsfile Corp. – January 28, 2022) – Quinsam Capital Corporation (CSE: QCA) (“Quinsam” or the “Company”) wishes to announce the declaration of its regular quarterly dividend.

Dividend

The Board of Directors of Quinsam has approved the Company’s 30th consecutive quarterly dividend. The dividend is $0.00125 per share ($0.005 per share per year). The distribution will be paid on February 25, 2022 to shareholders of record on February 4, 2022. This dividend will be designated as an “eligible dividend” for Canadian income tax purposes. Future quarterly dividends will be subject to Board approval.

At the recent share price of $0.14, the current dividend yield is approximately 3.6%.

About Quinsam Capital Corporation

Quinsam is a merchant bank with a focus on “small cap” investments which it believes are undervalued. We do not invest on behalf of third parties or offer investment advice.

Generally, Quinsam does not believe that individual investments are material events. Quinsam may choose to announce certain investments once the company has finished buying its position because we feel that this information helps investors understand our decision-making process. Generally, Quinsam does not announce the sale of investments.

For further information contact:
Roger Dent, CEO
(647) 993-5475
roger@quinsamcapital.com

This press release may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events, which are inherently uncertain. Forward-looking statements can often, but not always, be identified by forward-looking words such as “anticipate”, “believe”, “continue”, “expect”, “goal”, “plan”, “intend”, “estimate”, “may”, “project”, “predict”, “potential”, “target”, and “will” or similar words suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance.

By their nature, forward-looking statements require making assumptions which include, among other things, that (i) Quinsam will have sufficient capital to effect its business strategies, (ii) the business strategies will produce the results intended by Quinsam, and (iii) the markets will react and perform in a manner consistent with the business strategies.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated. Quinsam believes that the expectations reflected in the forward-looking information are reasonable but no assurance can be given that these expectations will prove to be correct. Some risks and other factors that could cause actual results to differ materially from those expressed in forward-looking information in this press release include, but are not limited to: cannabis companies Quinsam has invested in obtaining and maintaining regulatory approvals including acquiring and renewing U.S. state, local or other licenses, and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization; market and general economic conditions of the cannabis sector or otherwise, interest rates, regulatory and statutory developments, the nature of the Company’s investments, the available opportunities and competition for investments, the concentration of our investments in certain industries and sectors, reliance on key personnel, risks affecting investments, management of the growth of the Company, and exchange rate fluctuations. Readers are cautioned that the foregoing list of risks and factors is not exhaustive. Although Quinsam has attempted to identify factors that could cause actual events or results to differ materially from those described in forward-looking information, there may be factors that cause events or results to differ from those intended, anticipated or estimated.

The forward-looking information contained herein is provided as at this date, based upon the opinions and estimates of management and information available to management as at this date. Quinsam does not undertake and specifically disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable law. Readers are cautioned not to place undue reliance on forward-looking information contained herein.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION BY ANY UNITED STATES NEWS DISTRIBUTION SERVICE

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111885

North America Legal Cannabis Market Report 2022: Market Size is Expected to Reach $38.2 Billion by 2028, Registering a CAGR of 16.6%

0

Dublin, Jan. 28, 2022 (GLOBE NEWSWIRE) — The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.

The North America legal cannabis market size is expected to reach USD 38.2 billion by 2028, registering a CAGR of 16.6% from 2022 to 2028. The rising legalization and growing use of marijuana for medical purposes are expected to propel market growth.

In addition, as countries in the region are actively liberalizing laws related to marijuana, the market is likely to witness increased demand for cannabis-based products as well as their derivatives. The marijuana segment dominated the market in 2021. The higher efficiency of marijuana-derived CBD is one of the crucial factors signifying the larger share of this segment.

The segment is also projected to grow at the fastest CAGR during the forecast period. The CBD segment dominated the market in 2021 due to the growing awareness about the positive effects of CBD for the treatment of various medical conditions, such as chronic pain, cancer & multiple sclerosis. In 2021, the recreational segment dominated the market.

The legalization of marijuana for adult use has driven the product demand in the recreational use application segment. In countries, such as Canada and the U.S., where marijuana for recreational use has been legalized, the market has witnessed a dynamic shift of patients from traditional methods or medicine to opting to use marijuana for medical and other purposes.

This can be attributed to the easy availability and low pricing. Moreover, an increase in the preference for Cannabidiol (CBD)-based products, such as food & beverages, cosmetics, and wellness products in the country supports market growth. Canada is anticipated to register the fastest growth rate during the forecast period.

Rising cannabis cultivation, the emergence of local players, favorable government initiatives, and increasing adoption of cannabis-based products are some of the key factors supporting the market growth in the country. The COVID-19 pandemic has substantially affected the market.

The supply chain disruptions and interruption in the transportation of cannabis & related raw materials, as a result of nationwide lockdown in the U.S. & Canada, hampered the market growth. In addition, panic-buying scenarios in these countries during the initial months of the pandemic led to a shortage in product stocks, thereby widening the demand-supply gap.

However, with situations heading toward normalcy, the cannabis-based product sales and the supply chain in the North American region are expected to stabilize and grow during the forecast period.

North America Legal Cannabis Market Report Highlights

  • The market is anticipated to have significant growth over the forecast period owing to rising legalization and growing use of marijuana for medical purposes
  • The marijuana segment dominated the market in 2021 owing to the growing adoption of marijuana products along with the increasing legalization of medical marijuana
  • In 2021, the CBD segment accounted for the highest revenue share owing to the increasing adoption of CBD for various medical purposes and growing awareness about affirmative effects of CBD for the treatment of various medical conditions
  • The recreational application segment accounted for the highest revenue share, owing to factors such as increased adoption of cannabis for recreational purposes and changing consumer behavior toward the use of cannabis
  • The U.S. is anticipated to be the largest market by 2028 owing to various factors, such as high awareness about cannabis-based products, the introduction of the 2018 Farm Bill that legalized hemp-derived products in the country, and an increase in the preference for Cannabidiol (CBD)-based products

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 North America Legal Cannabis Market: Variables, Trends & Scope
3.1 Market Segmentation
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing adoption of medical marijuana for treatment of chronic diseases
3.3.1.2 Elimination of black market through the legalization of medical marijuana
3.3.2 Market Restraint Analysis
3.3.2.1 High pricing of cannabis compared to illegal markets in the U.S.
3.3.2.2 Illicit cannabis trade due to surplus cultivation
3.4 Industry Analysis-SWOT Analysis, By Factor (Political & Legal, Economic, And Technological
3.5 Cannabis Market-Porter’s Analysis
3.6 History of Medical Use of Cannabis in North America
3.7 History of Industrial Use of Cannabis in North America
3.8 North America Legal Cannabis Number of clinical trials
3.9 Legal Cannabis Industry: Legalization Timeline in North America
3.9.1 Legalization Landscape (Timeline)
3.9.2 The U.S. Legalization Landscape
3.9.3 The Canada Legalization Landscape
3.9.4 North America Legal Cannabis Regulatory Scenario, By Country
3.10 North America Legal Cannabis Industry: Consumption Pattern Analysis
3.11 Trade Opportunity Analysis, by region
3.12 Legal Cannabis Industry: Country Case Study
3.12.1 U.S.
3.12.1.1 Legalization of Cannabis
3.12.1.2 Reason for Legalization
3.12.1.3 Scenario After Legalization and Consumer Attitude
3.12.1.4 Competitive Landscape Post Legalization
3.12.2 Canada
3.13 Human Abuse Liability Experience in North America Cannabis Market
3.14 Qualitative analysis on synthetic cannabinoids and cannabis in North America

Chapter 4 North America Legal Cannabis Market: Source Type Estimates & Trend Analysis
4.1 North America Legal Cannabis Market: Source Type Movement Analysis
4.2 North America Legal Cannabis Market: Source Type Analysis
4.2.1 Hemp
4.2.1.1 Hemp Market Estimates and Forecasts, 2016-2028 (USD Million)
4.2.1.2 Hemp CBD
4.2.1.3 Supplements
4.2.1.4 Industrial Hemp
4.2.2 Marijuana
4.2.2.1 Marijuana Market Estimates and Forecasts, 2016-2028 (USD Million)
4.2.2.2 Flower
4.2.2.3 Oils and Tinctures

Chapter 5 North America Legal Cannabis Market: Derivatives Type Estimates & Trend Analysis
5.1 North America Legal Cannabis Market: Derivatives Type Movement Analysis
5.2 North America Legal Cannabis Market: Derivatives Type Analysis
5.2.1 CBD
5.2.2 THC
5.2.3 Others

Chapter 6 North America Legal Cannabis Market: End-use Estimates & Trend Analysis
6.1 North America Legal Cannabis Market: End Use Movement Analysis
6.2 North America Legal Cannabis Market: End Use Analysis
6.2.1 Recreational Use
6.2.2 Medical Use
6.2.2.1 Medical Use Market Estimates and Forecasts, 2016-2028 (USD Million)
6.2.2.2 Chronic Pain
6.2.2.3 Cancer
6.2.2.4 Depression and Anxiety
6.2.2.5 Arthritis
6.2.2.6 Diabetes
6.2.2.7 Glaucoma
6.2.2.8 Migraines
6.2.2.9 Epilepsy
6.2.2.10 Multiple Sclerosis
6.2.2.11 AIDS
6.2.2.12 Amyotrophic Lateral Sclerosis (ALS)
6.2.2.13 Alzheimer’s
6.2.2.14 Post Traumatic Stress Disorder (PTSD)
6.2.2.15 Parkinson’s
6.2.2.16 Tourette’s
6.2.2.17 Others
6.2.3 Industrial Use
6.2.3.1 Textile
6.2.3.2 Non-Textile

Chapter 7 North America Legal Cannabis Market: Regional Estimates & Trend Analysis
7.1 North America Legal Cannabis Market: Region Movement Analysis, 2016-2028

Chapter 8 Competitive Analysis
8.1 Company Market Position Analysis
8.2 Recent Developments & Impact Analysis, By Key Market Participants
8.3 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.4 List of Tobacco Companies Investing in Cannabis

Chapter 9 Competitive Landscape

  • Canopy Growth Corporation
  • GW Pharmaceuticals, plc
  • Aurora Cannabis
  • Aphria, Inc. (Prior to the merger with Tilray)
  • Cronos Group
  • Tilray
  • Sundial Growers
  • Insys Therapeutics, Inc.
  • Vivo Cannabis Inc.
  • Cara Therapeutics, Inc

For more information about this report visit https://www.researchandmarkets.com/r/k6ifd


DRUNK ELEPHANT ARRIVES AT SHOPPERS DRUG MART

0

 

Starting this week, Canadian beauty lovers can stock up on one of the most popular skincare brands in the world – Drunk Elephant – at more than 100 convenient Shoppers Drug Mart locations and online at shoppersdrugmart.ca.

“Customers know that we have one of the hottest line ups of skincare and cosmetics in the country, and an extensive assortment so that there’s always something for everyone,” says Gwennaëlle Varnier, Vice President, Prestige Beauty, Shoppers Drug Mart.  “We are thrilled to add 40 different Drunk Elephant products to our line up, joining other leading global brands that we carry.  With the expertise in our stores, convenient locations in communities across the country and our PC Optimum loyalty program, there’s no better place for beauty in Canada.”

Over the years, Shoppers Drug Mart has grown its beauty department, expanding its offering of both emerging new brands as well as trusted favourites, all available at a variety of price points.

“I am so excited to be expanding our availability in Canada with Shoppers Drug Mart.” says Tiffany Masterson, founder of Drunk Elephant. “Our unique ingredient-elimination philosophy has been such a game changer for so many people. I can’t wait to continue educating on the Drunk Elephant difference and help those searching for a skincare solution.”

Canadians can choose from 40 different Drunk Elephant products at more than 100 Shoppers Drug Mart store locations including 6 Pharmaprix stores in Quebec, as well as online.

Sixth Wave Announces Filing of Preliminary Short Form Base Shelf Prospectus

0

Halifax, Nova Scotia–(Newsfile Corp. – January 27, 2022) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave or the Company“) is pleased to announce today that it has filed a preliminary short form base shelf prospectus (the “Prospectus”).

The Prospectus was filed with the securities regulatory authorities in each of the Provinces and Territories of Canada. The Prospectus was filed to provide the Company with financial flexibility and efficient access to Canadian capital markets to pursue its growth initiatives. A copy of the Prospectus is available under the Company’s profile on SEDAR at www.sedar.com.

Once a receipt for the final Prospectus is received from the applicable securities regulators, the final Prospectus will be valid for a 25-month period during which time the Company will be permitted to offer up to $25 million of common shares, warrants, subscription receipts, debt securities, or any combination thereof, including in the form of units (collectively, the “Securities“).

If any Securities are offered under the Prospectus, the terms of any such Securities and the intended use of the net proceeds resulting from such offering would be established at the time of any offering and would be described in a prospectus supplement filed with the applicable Canadian securities regulatory authorities at the time of such offering and would be made available by the Company.

This press release does not constitute an offer to sell or the solicitation of an offer to buy Securities, nor will there be any sale of the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under securities laws of any such jurisdiction.

The Canadian Securities Exchange has not reviewed, approved, or disapproved the content of this news release.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our web site at: www.sixthwave.com.

ON BEHALF OF THE BOARD OF DIRECTORS

Jon Gluckman
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed “forward-looking statements” including statements regarding the filing of a final Prospectus and the planned use of net proceeds of any financing. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs technology are subject to the risk that the AMIPs technology may not prove to be successful in detecting virus targets effectively or at all, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed development of a prototype for the product that is the subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111909